pharmaphorum August 7, 2024
The FDA has approved Servier’s vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.
The IDH1/2 inhibitor, which can be dosed orally and is designed to cross the blood-brain barrier into the central nervous system, is being marketed as Voranigo for patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
Specifically, it can be used after surgery including biopsy, sub-total resection, or gross total resection, and will be launched straight away at a list price of $39,881 a month, said the French pharma group. The EMA meanwhile is also in the midst of an accelerated assessment of the drug...
Today's Sponsors
Today's Sponsor